Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis
University of Dundee · Inserm · +24 more institutions
Abstract
In bronchiectasis, neutrophilic inflammation is associated with an increased risk of exacerbations and disease progression. Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP-1), targets neutrophil serine proteases, key mediators of neutrophilic inflammation.
); the annualized rate of severe exacerbations; and change in quality of life.
Citation impact
- FWCI
- 144.32
- Percentile
- 100%
- References
- 29
Authors
18- JDJames D. ChalmersCorresponding
University of Dundee
- PBPierre‐Régis Burgel
Inserm, Université Paris Cité, Hôpital Cochin, Assistance Publique – Hôpitaux de Paris, Institut Cochin
- CLCharles L. Daley
National Jewish Health, University of Colorado Denver
- ADAnthony De Soyza
Newcastle upon Tyne Hospitals NHS Foundation Trust, NIHR Newcastle Biomedical Research Centre, Newcastle University
- CHCharles Haworth
University of Cambridge, Papworth Hospital NHS Foundation Trust
Topics & keywords
- Bronchiectasis
- Medicine
- Internal medicine
- Lung